Clinical Trial Update: Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety, tolerability, and LDL-C reduction with evolocumab in HIV patients with hyperlipidemia/mixed dyslipidemia; completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• HIV Infection
• Hyperlipidemia

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Amgen | Conditions: Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection | Phase 3 | Status: COMPLETED | Results posted: 2020-07-21